BiomX (NYSEMKT:PHGE) Shares Down 14.9% – Should You Sell?

BiomX Inc. (NYSEMKT:PHGE) was down 14.9% on Thursday . The stock traded as low as $0.72 and last traded at $0.63. Approximately 53,300 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 61,836 shares. The stock had previously closed at $0.74.

BiomX Trading Down 14.9 %

The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $11.43 million, a P/E ratio of -0.84 and a beta of 1.38. The business has a 50-day moving average price of $0.75 and a two-hundred day moving average price of $0.79.

Institutional Trading of BiomX

Institutional investors and hedge funds have recently modified their holdings of the business. Ikarian Capital LLC bought a new stake in BiomX during the 3rd quarter worth $911,000. Alyeska Investment Group L.P. acquired a new position in shares of BiomX during the fourth quarter worth $632,000. JPMorgan Chase & Co. bought a new stake in shares of BiomX in the fourth quarter worth $314,000. Finally, Allostery Investments LP acquired a new stake in BiomX in the fourth quarter valued at $470,000. 40.57% of the stock is currently owned by institutional investors.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.